Patents by Inventor Matthew T. Basel

Matthew T. Basel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9731034
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: August 15, 2017
    Assignee: Kansas State University Research Foundation
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
  • Patent number: 9682155
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 20, 2017
    Assignee: Kansas State University Research Foundation
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
  • Patent number: 9216154
    Abstract: Supramolecular assemblies for delivering active agents to cancerous or precancerous tissues in a subject are provided. These supramolecular assemblies are also useful in assays for detecting and imaging of cancerous and precancerous cells. The assemblies are protease-sensitive and comprise a peptide linkage containing a protease consensus sequence. The assemblies can be selectively targeted to cancerous tissue where the protease enzymes degrade the peptide linkage thereby releasing the active agents which were physically or mechanically contained in or retained by the supramolecular assembly.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 22, 2015
    Assignee: Kansas State University Research Foundation
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel, Tej B. Shrestha, Hongwang Wang
  • Publication number: 20150132230
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
  • Publication number: 20150132785
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
  • Patent number: 8969027
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: March 3, 2015
    Assignee: Kansas State University Research Foundation
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
  • Publication number: 20130243741
    Abstract: A method for photodynamic therapy treatment of cancerous cells and tissue is provided. The method comprises administering tumor-trophic cells expressing a luminescent protein to a subject. A photosensitizing agent is then separately administered to the subject, followed by an optional iron chelator. On the day of treatment, a luminogenic substrate corresponding to the luminescent protein is administered to the subject. The substrate reacts with the luminescent protein in the vicinity of the cancerous tissue to produce light which activates the photosensitizing agent resulting in the selective destruction of the cancerous tissue.
    Type: Application
    Filed: September 19, 2011
    Publication date: September 19, 2013
    Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel, Tej B. Shrestha, Hongwang Wang
  • Publication number: 20120157824
    Abstract: The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.
    Type: Application
    Filed: August 31, 2010
    Publication date: June 21, 2012
    Applicants: NANOSCALE CORPORATION, KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Stefan H. Bossmann, Deryl Troyer, Matthew T. Basel, Thilani Nishanthika Samarakoon, Hongwang Wang, Viktor Chikan, Franklin Orban Kroh, Olga Barbara Koper, Brandon Ray Walker, Xiaoxuan Leaym
  • Publication number: 20110014125
    Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.
    Type: Application
    Filed: March 3, 2009
    Publication date: January 20, 2011
    Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel